ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Impact of clinical manifestations of vitiligo on patients’ quality of life of patients

Impact of clinical manifestations of vitiligo on patients’ quality of life of patients

Authors:
Валентина Вадимовна Петунина,
Виктория Юрьевна Васенова,
Екатерина Игоревна Цыганкова,
Евгения Владимировна Китарова,
Анастасия Сергеевна Юхатова,
Дмитрий Федорович Кашеваров

Журнал: Клиническая дерматология и венерология. 2026;25(5):737-744.

DOI: 10.17116/klinderma202625051737

Read: 703 раза

Download PDF (RU)Download PDF (EN)

Abstract

Vitiligo is classified as an acquired hypomelanosis with a genetic predisposition to autoimmune reactions. The disease presents with focal depigmentation. Vitiligo is often mistakenly regarded as a cosmetic defect, and proper examination and treatment are neglected. The clinical manifestations of the disease have a significant impact on patients’ quality of life. This article is devoted to a comprehensive analysis of the psychosocial aspects of vitiligo and their impact on patients’ quality of life. In addition to investigating the etiology, pathogenesis, and clinical manifestations of the disease, the psychological status and quality of life of patients are considered in detail. Particular attention is paid to factors determining the degree of quality of life impairment in vitiligo, including gender differences, age, lesion location, and the patient’s socioeconomic status. It has been established that the presence of depigmentation lesions on exposed areas of the body significantly exacerbates the psychological burden of the disease and impedes patients’ social adaptation. The results of large international studies, demonstrating the significant impact of vitiligo on the emotional state and social adaptation of patients, are presented. This article highlights the need for a comprehensive approach to vitiligo management, including not only dermatological but also psychological support. The findings can be used to develop effective treatment and support strategies for patients with vitiligo.

Keywords

  • vitiligo
  • quality of life
  • questionnaire
  • hypopigmentation
  • psychodermatology
  • quality of life assessment

Участие авторов

Authors’ contributions:

The concept and design of the study — Petunina V.V.

Collecting and interpreting the data — Petunina V.V., Tsygankova E.I., Kitarova E.V., Yukhatova A.S., Kashevarov D.F.

Drafting the manuscript — Petunina V.V., Tsygankova E.I.

Revising and approval the manuscript — Petunina V.V., Vasenova V.Yu.

Конфликт интересов

The authors declare no conflict of interest.

Дата поступления: 24.04.2025

Дата принятия в печать: 16.07.2026

Дата публикации: 10.11.2026

References
  1. Koshevenko YuN. Vitiligo. Clinic, etiology, pathogenesis, treatment, rehabilitation, prevention. M.: Medicine; 2002. (In Russ.).
  2. Taïeb A, Picardo M; VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20(1):27-35. https://doi.org/10.1111/j.1600-0749.2006.00355.x
  3. Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009; 28(2):86-92. https://doi.org/10.1016/j.sder.2009.04.008
  4. Kruglova LS. Vitiligo: modern views on the etiology and methods of therapy. Russian Journal of Skin and Venereal Diseases. 2016;19(4):241-244. (In Russ.).
  5. Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621-648. https://doi.org/10.1146/annurev-immunol-100919-023531
  6. Silverberg JI, Silverberg NB. Vitiligo disease triggers: psychological stressors preceding the onset of disease. Cutis. 2015;95(5):255-262.
  7. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25(3):E1-13. https://doi.org/10.1111/j.1755-148X.2012.00997.x
  8. Ucuz I, Altunisik N, Sener S, Turkmen D, Kavuran NA, Marsak M, et al. Quality of life, emotion dysregulation, attention deficit and psychiatric comorbidity in children and adolescents with vitiligo. Clin Exp Dermatol. 2020;16:22. https://doi.org/10.1111/ced.14196
  9. Chen CY, Wang WM, Chung CH, Tsao CH, Chien WC, Hung CT. Increased risk of psychiatric disorders in adult patients with vitiligo: a nationwide, population-based cohort study in Taiwan. J Dermatol. 2020;47:470-475. https://doi.org/10.1111/1346-8138.15290
  10. Petunina VV, Potekaev NN, Zhukova OV. Research trends in vitiligo development mechanisms and concomitant autoimmune conditions. Russian Journal of Clinical Dermatology and Venereology. 2022;21(3):291-295. (In Russ.). https://doi.org/10.17116/klinderma202221031291
  11. Chang Y, Zhang S, Zhang W, Li S, Li C. The Efficacy and Psychoneuroimmunology Mechanism of Camouflage Combined With Psychotherapy in Vitiligo Treatment. Front Med (Lausanne). 2022;9:818543. https://doi.org/10.3389/fmed.2022.818543
  12. Al-Harbi M. Prevalence of depression in vitiligo patients. Skinmed. 2013;11(6):327-330.
  13. Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry. 1979;1(1):73-77. https://doi.org/10.1016/0163-8343(79)90081-1
  14. Silverberg JI, Silverberg NB. Association Between Vitiligo Extent and Distribution and Quality-of-Life Impairment. JAMA Dermatol. 2013;149(2): 159-164. https://doi.org/10.1001/jamadermatol.2013.927
  15. Varzhapetyan AA, Dorozhenok IYu, Lomonosov KM. Vitiligo and comorbid psychosomatic disorders. Russian Journal of Skin and Venereal Diseases. 2019;22(1-2):33-38. (In Russ.).
  16. Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self‐reported health‐related quality of life. British Journal of Dermatology. 2005;152(6):1165-1172. https://doi.org/10.1111/j.1365-2133.2005.06456.x
  17. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003;1:58. https://doi.org/10.1186/1477-7525-1-58
  18. Ezzedine K, Grimes PE, Meurant JM, Seneschal J, Léauté-Labrèze C, Ballanger F, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173(2):607-609. https://doi.org/10.1111/bjd.13839
  19. Merhi S, Salameh P, Abboud M, Seneschal J, Eleftheriadou V, Pane I, et al. Facial involvement is reflective of patients’ global perception of vitiligo extent. Br J Dermatol. 2023;189(2):188-194. https://doi.org/10.1093/bjd/ljad109
  20. Bibeau K, Ezzedine K, Harris JE, et al. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study. JAMA Dermatol. 2023;159(10):1124-1128. https://doi.org/10.1001/jamadermatol.2023.2787
  21. Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022;36(9):1507-1523. https://doi.org/10.1111/jdv.18129
  22. Dertlioğlu SB, Cicek D, Balci DD, Halisdemir N. Dermatology life quality index scores in children with vitiligo: comparison with atopic dermatitis and healthy control subjects. Int J Dermatol. 2013;52(1):96-101. https://doi.org/10.1111/j.1365-4632.2012.05616.x
  23. Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11-8. https://doi.org/10.1016/j.jaad.2012.01.038
  24. Gupta V, Sreenivas V, Mehta M, Ramam M. What do Vitiligo Impact Scale-22 scores mean? Studying the clinical interpretation of scores using an anchor-based approach. Br J Dermatol. 2019;180(3):580-585. https://doi.org/10.1111/bjd.17040
  25. Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A. Patients’ perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2021;35(3):744-748. https://doi.org/10.1111/jdv.16927
  26. Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5-19. https://doi.org/10.1111/j.1365-2133.2012.11197.x
  27. Abdel-Malek ZA, Jordan C, Ho T, Upadhyay PR, Fleischer A, Hamzavi I. The enigma and challenges of vitiligo pathophysiology and treatment. Pigment Cell Melanoma Res. 2020;33:778-787. https://doi.org/10.1111/pcmr.12878
  28. Passeron T. Medical and Maintenance Treatments for Vitiligo. Dermatol Clin. 2017;35:163-170. https://doi.org/10.1016/j.det.2016.11.007
  29. Rajatanavin N, Suwanachote S, Kulkollakarn S. Dihydroxyacetone: a safe camouflaging option in vitiligo. Int J Dermatol. 2008;47:402-406. https://doi.org/10.1111/j.1365-4632.2008.03356.x
  30. Tanioka M, Yamamoto Y, Kato M, Miyachi Y. Camouflage for patients with vitiligo vulgaris improved their quality of life. J Cosmet Dermatol. 2010;9:72-75. https://doi.org/10.1111/j.1473-2165.2010.00479.x
  31. Bassiouny D, Hegazy R, Esmat S, Gawdat HI, Ahmed Ezzat M, Tawfik HA, et al. Cosmetic camouflage as an adjuvant to vitiligo therapies: effect on quality of life. J Cosmet Dermatol. 2021;20:159-165. https://doi.org/10.1111/jocd.13459
  32. Rousseau K, Kauser S, Pritchard LE, Warhurst A, Oliver RL, Slominski A, et al. Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis. FASEB J. 2007;21:1844-1856. https://doi.org/10.1096/fj.06-7398com
  33. Pal SK, Ghosh KK, Panja RK, Banerjee PK. Adrenocortical function in vitiligo. Clin Chim Acta. 1981;113:325-327. https://doi.org/10.1016/0009-8981(81)90286-2
slide-cover

Recommended articles:

Assessment of quality of life as a criterion for the effectiveness of treatment of patients with rosacea (according to two clinical cases).Journal of Adaptive Medical Immunology and Public Health Issues. 2026;2(2-3):72-78

Clinical and laboratory features and quality of life of children with severe bronchial asthma.Journal of Adaptive Medical Immunology and Public Health Issues. 2026;2(2-3):41-48

Complex non-drug therapies in patients with vasovagal syncope, adherence to treatment and quality of life.Russian Cardiology Bulletin. 2026;21(3):74-82

Experience in using a TAP block during TAPP surgery for inguinal hernia in a short-stay hospital setting.Endoscopic Surgery. 2026;32(5):48-54

Evaluation of spike formation and quality of life in patients with primary midline ventral hernias after endoscopic eTEP Sublay and IPOM surgeries: a cohort study.Endoscopic Surgery. 2026;32(5):20-29

Chronic bronchitis in outpatient practice: unsolved diagnostic problems and therapeutic challenges.Russian Journal of Preventive Medicine. 2026;29(9):110-115

Awareness and attitudes of Russian physicians about breast arterial calcification — a new marker of cardiovascular risk in women.Russian Journal of Preventive Medicine. 2026;29(9):7-14

Prevalence of mental disorders and syndromic mental distress in patients with chronic dermatoses: A cross-sectional epidemiological study.S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(7):107-114

Skin hypopigmentation: modern approaches to classification, pathogenesis and differential diagnosis.Russian Journal of Clinical Dermatology and Venereology. 2026;25(3):347-354

Onychomycosis as a sociomedical problem: assessment of patients’ quality of life with the modified OnyCOE-T questionnaire.Russian Journal of Clinical Dermatology and Venereology. 2026;25(1):40-46

Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29
  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12
  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru
  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026